Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.54

€8.54

0.060%
0.005
0.060%
-
 
12.06.26 / Tradegate WKN: A0Q6J0 / Name: Zur Rose Group / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Zur Rose Group AG Stock

There is nearly no change for the Zur Rose Group AG stock today. Compared to yesterday it only changed by €0.005.
Criterium "Valuation (undervalued/overvalued)" is seen as the biggest plus for Zur Rose Group AG stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Zur Rose Group AG in the next few years

Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
DocMorris publishes invitation to the Annual General Meeting
DocMorris publishes invitation to the Annual General Meeting
DocMorris publishes invitation to the Annual General Meeting
DocMorris achieves strong revenue growth in Q1 2026 – on track for EBITDA break-even
DocMorris achieves strong revenue growth in Q1 2026 – on track for EBITDA break-even
DocMorris achieves strong revenue growth in Q1 2026 – on track for EBITDA break-even